May 2016 DOI 10.14302/issn.2377-2549.jndc-15-923
Wang FengqingCorresponding author
Key Laboratory of Pharmaceutical, College of Pharmaceutical Sciences, Hebei University, Baoding, 071000, P. R. China.
A hybrid monolithic column was prepared using octavinyloctasilasesquioxane (OVS) as a monomer, benzoyl peroxide/dimethylacetamide (BPO/DMA) as initiator, ethylene glycol dimethacrylate (EDMA) as cross-linker, 1-dodecanol as porogenic agent and dimethylbenzene as cosolvent. A tidy skeleton, much bigger specific surface area (22.4 m2/g) and lower swelling property of the monolithic column with OVS added than the one without OVS added were determined with Scanning Electron Microscopy (SEM), Nitrogen adsorption/desorption measurements (BET) and swelling test with elute of different concentration of acetonitrile in water. Fourier-transform infrared spectra (FTIR) was taken to characterize the composition of groups. Moreover, a better separation performance for benzene series compounds under reversed phase liquid chromatography (RPLC) mode was obtained using the monolithic columns with OVS added than those without.
Aug 2026
Reddy Pallerla ManjulaCorresponding author
Cyclic peptides are expected to play a significant role in the future of drug discovery and development. Their unique properties, such as enhanced target affinity, metabolic stability, and favorable pharmokinetic profiles, make them promising candidates for addressing complex therapeutic targets. Innovations in design and synthetic techniques, including phage display and genetic code expansion with noncanonical amino acids, are enabling the development of diverse cyclic peptide libraries. These advancements are expected to bridge the gap between traditional small molecules and biologics, offering significant promise in the treatment of complex diseases. The therapeutic potential of cyclic peptides is broad, with applications in various pharmacological activities, including antibiotics, antifungals, anticancer, and immunosuppressants. The number of cyclic peptide drugs under research has reached hundreds, some have entered the late clinical stage. With ongoing research, more cyclic peptide drugs are expected to be approved and enter the market in the future. Cyclic peptides are also valuable research tools, suitable for probes that selectively modulate target proteins or high affinity ligands for biomolecular imaging. The development of selection strategies and various cyclization strategies, non-natural amino acids, and functional building blocks further enhance their functionality and utility in drug development. In summary, Cyclic peptides are poised to be a valuable class of molecules in the future, with ongoing research and development efforts aimed at optimizing their properties and expanding their therapeutic applications. .